316 related articles for article (PubMed ID: 28279499)
1. Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.
Galiè N; Denton CP; Dardi F; Manes A; Mazzanti G; Li B; Varanese L; Esler A; Harmon C; Palazzini M
Int J Cardiol; 2017 May; 235():67-72. PubMed ID: 28279499
[TBL] [Abstract][Full Text] [Related]
2. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
Oudiz RJ; Brundage BH; Galiè N; Ghofrani HA; Simonneau G; Botros FT; Chan M; Beardsworth A; Barst RJ;
J Am Coll Cardiol; 2012 Aug; 60(8):768-74. PubMed ID: 22818063
[TBL] [Abstract][Full Text] [Related]
3. Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
Rhee RL; Gabler NB; Praestgaard A; Merkel PA; Kawut SM
Arthritis Rheumatol; 2015 Sep; 67(9):2457-65. PubMed ID: 26016953
[TBL] [Abstract][Full Text] [Related]
4. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.
Rhee RL; Gabler NB; Sangani S; Praestgaard A; Merkel PA; Kawut SM
Am J Respir Crit Care Med; 2015 Nov; 192(9):1111-7. PubMed ID: 26291092
[TBL] [Abstract][Full Text] [Related]
6. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
Kuwana M; Blair C; Takahashi T; Langley J; Coghlan JG
Ann Rheum Dis; 2020 May; 79(5):626-634. PubMed ID: 32161055
[TBL] [Abstract][Full Text] [Related]
7. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
[TBL] [Abstract][Full Text] [Related]
8. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.
Humbert M; Coghlan JG; Ghofrani HA; Grimminger F; He JG; Riemekasten G; Vizza CD; Boeckenhoff A; Meier C; de Oliveira Pena J; Denton CP
Ann Rheum Dis; 2017 Feb; 76(2):422-426. PubMed ID: 27457511
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue disease-associated pulmonary arterial hypertension.
Ramjug S; Hussain N; Hurdman J; Elliot CA; Sabroe I; Armstrong IJ; Billings C; Hamilton N; Kiely DG; Condliffe R
Respirology; 2017 Feb; 22(2):372-377. PubMed ID: 27651181
[TBL] [Abstract][Full Text] [Related]
10. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.
Badesch DB; Hill NS; Burgess G; Rubin LJ; Barst RJ; Galiè N; Simonneau G;
J Rheumatol; 2007 Dec; 34(12):2417-22. PubMed ID: 17985403
[TBL] [Abstract][Full Text] [Related]
11. Tadalafil: in pulmonary arterial hypertension.
Croxtall JD; Lyseng-Williamson KA
Drugs; 2010 Mar; 70(4):479-88. PubMed ID: 20205489
[TBL] [Abstract][Full Text] [Related]
12. Effects of dose and age on adverse events associated with tadalafil in the treatment of pulmonary arterial hypertension.
Berman-Rosenzweig E; Arneson C; Klinger JR
Pulm Circ; 2014 Mar; 4(1):45-52. PubMed ID: 25006420
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
Li M; Jing ZC; Li Y; Huo Y; Yu Z; Zhang G; Zhu P; Liu J; Ji Q; Wu B; Zhong J; Wang P; Zhu W; Zeng X
BMC Cardiovasc Disord; 2020 Jul; 20(1):339. PubMed ID: 32680480
[TBL] [Abstract][Full Text] [Related]
14. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
15. Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis.
Pan J; Lei L; Zhao C
Clin Exp Rheumatol; 2018; 36(6):1095-1102. PubMed ID: 29998831
[TBL] [Abstract][Full Text] [Related]
16. The short-term role of corticosteroid therapy for pulmonary arterial hypertension associated with connective tissue diseases: report of five cases and a literature review.
Kato M; Kataoka H; Odani T; Fujieda Y; Otomo K; Oku K; Horita T; Yasuda S; Atsumi T; Ohira H; Tsujino I; Nishimura M; Koike T
Lupus; 2011 Oct; 20(10):1047-56. PubMed ID: 21676917
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension.
Langleben D; Orfanos SE; Giovinazzo M; Hirsch A; Baron M; Senécal JL; Armaganidis A; Catravas JD
Arthritis Rheum; 2008 Apr; 58(4):1156-64. PubMed ID: 18383374
[TBL] [Abstract][Full Text] [Related]
18. Decreased circulating thrombomodulin is improved by tadalafil therapy in hypoxemic patients with advanced pulmonary arterial hypertension.
Maeda NY; Clavé MM; Bydlowski SP; Lopes AA
Thromb Res; 2016 Oct; 146():15-19. PubMed ID: 27564658
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model.
Ferguson-Sells L; Velez de Mendizabal N; Li B; Small D
Clin Pharmacokinet; 2022 Feb; 61(2):249-262. PubMed ID: 34379314
[TBL] [Abstract][Full Text] [Related]
20. Metabolomic Differences in Connective Tissue Disease-Associated Versus Idiopathic Pulmonary Arterial Hypertension in the PVDOMICS Cohort.
Simpson CE; Hemnes AR; Griffiths M; Grunig G; Tang WHW; Garcia JGN; Barnard J; Comhair SA; Damico RL; Mathai SC; Hassoun PM;
Arthritis Rheumatol; 2023 Dec; 75(12):2240-2251. PubMed ID: 37335853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
